VEA
EPZM

Virtus ETF Advisers’s Epizyme, Inc EPZM Stock Holding History

Virtus ETF Advisers’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-51,919
Closed -$266K – 415
2021
Q3 		$266K Sell
51,919
-4,755
-8% -$28.9K 0.12% 212
2021
Q2 		$471K Buy
56,674
+8,726
+18% +$73.6K 0.19% 169
2021
Q1 		$418K Buy
47,948
+1,310
+3% +$13.6K 0.18% 175
2020
Q4 		$506K Buy
46,638
+12,952
+38% +$160K 0.21% 139
2020
Q3 		$402K Buy
33,686
+2,837
+9% +$38K 0.21% 169
2020
Q2 		$495K Buy
30,849
+10,543
+52% +$184K 0.23% 149
2020
Q1 		$315K Sell
20,306
-2,966
-13% -$63.7K 0.13% 221
2019
Q4 		$572K Buy
23,272
+1,552
+7% +$23K 0.09% 195
2019
Q3 		$224K Sell
21,720
-1,210
-5% -$15.3K 0.05% 229
2019
Q2 		$288K Sell
22,930
-22,532
-50% -$290K 0.06% 235
2019
Q1 		$563K Sell
45,462
-5,376
-11% -$60.1K 1.2% 26
2018
Q4 		$313K Buy
50,838
+20,983
+70% +$160K 0.05% 97
2018
Q3 		$316K Sell
29,855
-21,348
-42% -$244K 0.03% 184
2018
Q2 		$694K Sell
51,203
-8,127
-14% -$126K 0.61% 103
2018
Q1 		$1.05M Buy
59,330
+31,789
+115% +$537K 0.91% 35
2017
Q4 		$346K Buy
27,541
+832
+3% +$12.1K 0.43% 98
2017
Q3 		$509K Buy
26,709
+2,443
+10% +$37.3K 0.07% 88
2017
Q2 		$366K Sell
24,266
-1,062
-4% -$16.1K 0.05% 82
2017
Q1 		$434K Buy
25,328
+2,428
+11% +$32.3K 0.08% 110
2016
Q4 		$277K Buy
22,900
+1,150
+5% +$12K 0.08% 117
2016
Q3 		$214K Hold
21,750
– – 0.1% 136
2016
Q2 		$223K Buy
21,750
+5,350
+33% +$59.7K 0.17% 120
2016
Q1 		$199K Buy
+16,400
New +$166K 0.27% 83

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

Virtus ETF Advisers's EPZM Position: Q4 2021 in Review

Virtus ETF Advisers sold out of Epizyme, Inc (EPZM) in Q4 2021, closing a stake of 51,919 shares — an estimated $266K sold.

Virtus ETF Advisers first reported a position in EPZM in Q1 2016 and held it in 23 quarters. The position peaked at $1.05M in Q1 2018. 132 funds tracked by Wall St. Rank hold EPZM as of Q4 2021.

  • Virtus ETF Advisers reported no remaining Epizyme, Inc position as of Q4 2021 after selling out during the quarter.
  • Virtus ETF Advisers sold 51,919 Epizyme, Inc shares in Q4 2021, an estimated $266K.
  • Virtus ETF Advisers first reported a position in Epizyme, Inc in Q1 2016 and held it in 23 quarters.
  • Virtus ETF Advisers's Epizyme, Inc position peaked at $1.05M in Q1 2018.
  • 132 funds tracked by Wall St. Rank held Epizyme, Inc as of Q4 2021.

Based on Virtus ETF Advisers's 13F filing for Q4 2021, filed 14 Feb 2022.